Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab in PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR Advanced Colorectal Cancer
NCT05426005Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2023
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Started Feb 2023; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05426005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426005.